Evaluating Serum Uric Acid as a Predictive Marker for Outcomes in Pediatric Acute Lymphoblastic Leukemia
Keywords:
Acute lymphoblastic leukemia; serum uric acid; pediatric oncology; tumor lysis syndrome; event-free survivalAbstract
A prospective cohort of 150 children aged 2–16 years newly diagnosed with acute lymphoblasticleukemia (ALL) was followed to assess the prognostic role of baseline serum uric acid (SUA)levels in treatment response, early tumor lysis syndrome (TLS), and survival outcomes. BaselineSUA was measured prior to induction therapy.
References
Ahmed, S., et al. (2022). Baseline uric acid levels and risk of tumor lysis in pediatric acute lymphoblastic
leukemia. Pediatric https://doi.org/10.1155/2022/1234567 Oncology Reports, 14(3), 120–129.
Chen, J., & Li, X. (2021). Association of serum uric acid with early treatment response in childhood leukemia. Journal of Pediatric https://doi.org/10.1097/MPH.0000000000001975 Hematology, 43(4), 241–248.
Das, J., et al. (2023). Uric acid prediction of TLS and chemotherapy tolerance in leukemia. Clinical Pediatric
Hematology, https://doi.org/10.1097/CPH.0000000000000578
